AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved by the European Commission as a maintenance treatment for asthma in patients aged 12 and over whose condition is not adequately controlled with medium-dose inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination therapy. The single-inhaler triple combination adds a long-acting muscarinic antagonist (LAMA) to ICS/LABA treatment. […]
The post AstraZeneca’s Trixeo approved in EU for asthma in patients aged 12 and over appeared first on Pharmafile.